Pages that link to "Q58447894"
Jump to navigation
Jump to search
The following pages link to Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction (Q58447894):
Displaying 50 items.
- ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies (Q24289195) (← links)
- No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction (Q26740252) (← links)
- Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists (Q26749495) (← links)
- Reducing myocardial infarct size: challenges and future opportunities (Q26775395) (← links)
- The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis (Q26795473) (← links)
- Myocardial reperfusion injury: looking beyond primary PCI (Q26991482) (← links)
- Postconditioning signalling in the heart: mechanisms and translatability (Q27021021) (← links)
- Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery (Q28072918) (← links)
- Remote ischaemic conditioning in the context of type 2 diabetes and neuropathy: the case for repeat application as a novel therapy for lower extremity ulceration (Q28078462) (← links)
- Cardioprotection: Where to from here? (Q30244797) (← links)
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus (Q30249371) (← links)
- Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon (Q30583012) (← links)
- Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas (Q33603384) (← links)
- Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI) (Q33606173) (← links)
- Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance (Q33720141) (← links)
- Novel adjunctive treatments of myocardial infarction (Q33812924) (← links)
- Adjuvant cardioprotection in cardiac surgery: update. (Q34120490) (← links)
- Cardiovascular effects of incretin therapy in diabetes care (Q34171759) (← links)
- Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial (Q34297010) (← links)
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure (Q34336097) (← links)
- Remote ischemic conditioning. (Q34458416) (← links)
- Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes (Q34771795) (← links)
- Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes (Q34994502) (← links)
- Cardiovascular remodelling in coronary artery disease and heart failure (Q35090566) (← links)
- Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction (Q35121830) (← links)
- Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study (Q35174285) (← links)
- Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis (Q35227453) (← links)
- Predictors and prognostic value of left atrial remodelling after acute myocardial infarction. (Q35722052) (← links)
- Penehyclidine Hydrochloride Preconditioning Provides Cardioprotection in a Rat Model of Myocardial Ischemia/Reperfusion Injury (Q35859797) (← links)
- Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus (Q35926588) (← links)
- A Role for Photobiomodulation in the Prevention of Myocardial Ischemic Reperfusion Injury: A Systematic Review and Potential Molecular Mechanisms. (Q36274955) (← links)
- Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial (Q36297833) (← links)
- Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes (Q36302662) (← links)
- Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials (Q36305825) (← links)
- Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside (Q36371672) (← links)
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. (Q36406821) (← links)
- Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure (Q36454284) (← links)
- Cardiovascular biology of the incretin system (Q36484283) (← links)
- Myocardial ischemia-reperfusion injury: a neglected therapeutic target. (Q36497176) (← links)
- Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway (Q36520207) (← links)
- Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study (Q36625415) (← links)
- Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction (Q36694694) (← links)
- Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism (Q36796024) (← links)
- Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis. (Q36836016) (← links)
- Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus (Q36972371) (← links)
- GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial (Q37057824) (← links)
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study (Q37125983) (← links)
- Conditioning the heart to prevent myocardial reperfusion injury during PPCI (Q37140973) (← links)
- Cardiometabolic interventions - focus on transcriptional regulators (Q37161933) (← links)
- Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study (Q37172662) (← links)